Emerging antibacterial and antiviral drugs for treating respiratory tract infections

Research output: Contribution to journalReview article

Abstract

Introduction: Management of LRTI is becoming more frequently challenging since the emergence of multidrug resistance bacteria and the increase of severe viral infection, reducing the number of available effective drugs. The clinical evaluation of new therapeutic associations is mandatory to cope with the increases in resistance, in association with better infection control and antimicrobial policies. Areas covered: We searched Pubmed in English language of phase I, II, III clinical trials and approved treatments for LRTI, between 2006 and 2016. Expert opinion:Development of new molecules or new combinations regimens are very important for patients with severe infections and in specific subgroups of patients like CF and bronchiectatic patients. Standardized protocols for antibiotic stewardship in difficult-to-treat infections are the next step. Moreover, non-antibiotic treatments and preventive strategies as vaccination need to be part of clinical practice.

Original languageEnglish
Pages (from-to)185-199
Number of pages15
JournalExpert Opinion on Emerging Drugs
Volume23
Issue number3
DOIs
Publication statusPublished - Jul 3 2018

Fingerprint

Respiratory Tract Infections
Antiviral Agents
Expert Testimony
Multiple Drug Resistance
Virus Diseases
Infection Control
Infection
PubMed
Vaccination
Language
Therapeutics
Clinical Trials
Anti-Bacterial Agents
Bacteria
Pharmaceutical Preparations

Keywords

  • antibiotics
  • cystic fibrosis
  • Gram-negative
  • Gram-positive
  • Lower-respiratory tract infections

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging antibacterial and antiviral drugs for treating respiratory tract infections. / Mantero, Marco; Rogliani, Paola; Cazzola, Mario; Blasi, Francesco; Di Pasquale, Marta.

In: Expert Opinion on Emerging Drugs, Vol. 23, No. 3, 03.07.2018, p. 185-199.

Research output: Contribution to journalReview article

@article{d63a46ab05b94ed8a8db56397204bf7c,
title = "Emerging antibacterial and antiviral drugs for treating respiratory tract infections",
abstract = "Introduction: Management of LRTI is becoming more frequently challenging since the emergence of multidrug resistance bacteria and the increase of severe viral infection, reducing the number of available effective drugs. The clinical evaluation of new therapeutic associations is mandatory to cope with the increases in resistance, in association with better infection control and antimicrobial policies. Areas covered: We searched Pubmed in English language of phase I, II, III clinical trials and approved treatments for LRTI, between 2006 and 2016. Expert opinion:Development of new molecules or new combinations regimens are very important for patients with severe infections and in specific subgroups of patients like CF and bronchiectatic patients. Standardized protocols for antibiotic stewardship in difficult-to-treat infections are the next step. Moreover, non-antibiotic treatments and preventive strategies as vaccination need to be part of clinical practice.",
keywords = "antibiotics, cystic fibrosis, Gram-negative, Gram-positive, Lower-respiratory tract infections",
author = "Marco Mantero and Paola Rogliani and Mario Cazzola and Francesco Blasi and {Di Pasquale}, Marta",
year = "2018",
month = "7",
day = "3",
doi = "10.1080/14728214.2018.1504020",
language = "English",
volume = "23",
pages = "185--199",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Emerging antibacterial and antiviral drugs for treating respiratory tract infections

AU - Mantero, Marco

AU - Rogliani, Paola

AU - Cazzola, Mario

AU - Blasi, Francesco

AU - Di Pasquale, Marta

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Introduction: Management of LRTI is becoming more frequently challenging since the emergence of multidrug resistance bacteria and the increase of severe viral infection, reducing the number of available effective drugs. The clinical evaluation of new therapeutic associations is mandatory to cope with the increases in resistance, in association with better infection control and antimicrobial policies. Areas covered: We searched Pubmed in English language of phase I, II, III clinical trials and approved treatments for LRTI, between 2006 and 2016. Expert opinion:Development of new molecules or new combinations regimens are very important for patients with severe infections and in specific subgroups of patients like CF and bronchiectatic patients. Standardized protocols for antibiotic stewardship in difficult-to-treat infections are the next step. Moreover, non-antibiotic treatments and preventive strategies as vaccination need to be part of clinical practice.

AB - Introduction: Management of LRTI is becoming more frequently challenging since the emergence of multidrug resistance bacteria and the increase of severe viral infection, reducing the number of available effective drugs. The clinical evaluation of new therapeutic associations is mandatory to cope with the increases in resistance, in association with better infection control and antimicrobial policies. Areas covered: We searched Pubmed in English language of phase I, II, III clinical trials and approved treatments for LRTI, between 2006 and 2016. Expert opinion:Development of new molecules or new combinations regimens are very important for patients with severe infections and in specific subgroups of patients like CF and bronchiectatic patients. Standardized protocols for antibiotic stewardship in difficult-to-treat infections are the next step. Moreover, non-antibiotic treatments and preventive strategies as vaccination need to be part of clinical practice.

KW - antibiotics

KW - cystic fibrosis

KW - Gram-negative

KW - Gram-positive

KW - Lower-respiratory tract infections

UR - http://www.scopus.com/inward/record.url?scp=85055437966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055437966&partnerID=8YFLogxK

U2 - 10.1080/14728214.2018.1504020

DO - 10.1080/14728214.2018.1504020

M3 - Review article

C2 - 30032674

AN - SCOPUS:85055437966

VL - 23

SP - 185

EP - 199

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 3

ER -